Cargando…

BRD4 Inhibitor AZD5153 Suppresses the Proliferation of Colorectal Cancer Cells and Sensitizes the Anticancer Effect of PARP Inhibitor

Background: Bromodomain-containing protein 4(BRD4) is reported to play a vital role in the development of numerous malignant diseases, which is considered as a promising target for cancer therapy. AZD5153, a novel specific BRD4 inhibitor, showed potent anticancer effects in several cancer types, but...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Peng, Li, Ruidong, Xiao, Hua, Liu, Weizhen, Zeng, Xiangyu, Xie, Genchen, Yang, Wenchang, Shi, Liang, Yin, Yuping, Tao, Kaixiong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2019
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6743290/ https://www.ncbi.nlm.nih.gov/pubmed/31523195 http://dx.doi.org/10.7150/ijbs.34162

Ejemplares similares

BRD4 Inhibitor AZD5153 Suppresses the Proliferation of Colorectal Cancer Cells and Sensitizes the Anticancer Effect of PARP Inhibitor: Erratum
por: Zhang, Peng, et al.
Publicado: (2022)

AZD5153, a Bivalent BRD4 Inhibitor, Suppresses Hepatocarcinogenesis by Altering BRD4 Chromosomal Landscape and Modulating the Transcriptome of HCC Cells
por: Lin, Cho-Hao, et al.
Publicado: (2022)

Translational Modeling of Drug‐Induced Myelosuppression and Effect of Pretreatment Myelosuppression for AZD5153, a Selective BRD4 Inhibitor
por: Collins, TA, et al.
Publicado: (2017)

BRD4 Inhibition by AZD5153 Promotes Antitumor Immunity via Depolarizing M2 Macrophages
por: Li, Xi, et al.
Publicado: (2020)

First-in-human Study of AZD5153, A Small-molecule Inhibitor of Bromodomain Protein 4, in Patients with Relapsed/Refractory Malignant Solid Tumors and Lymphoma
por: Hamilton, Erika P., et al.
Publicado: (2023)

Targeting MUS81 promotes the anticancer effect of WEE1 inhibitor and immune checkpoint blocking combination therapy via activating cGAS/STING signaling in gastric cancer cells
por: Li, Chengguo, et al.
Publicado: (2021)

Combination of PARP inhibitor and CDK4/6 inhibitor modulates cGAS/STING‐dependent therapy‐induced senescence and provides “one‐two punch” opportunity with anti‐PD‐L1 therapy in colorectal cancer
por: Wang, Tao, et al.
Publicado: (2023)

Synergistic effect of PARP inhibitor and BRD4 inhibitor in multiple models of ovarian cancer
por: Huang, Yuhan, et al.
Publicado: (2023)

The lysyl oxidase like 2/3 enzymatic inhibitor, PXS‐5153A, reduces crosslinks and ameliorates fibrosis
por: Schilter, Heidi, et al.
Publicado: (2018)

PARP inhibitors: current status and implications for anticancer therapeutics
por: Usmani, Hadi, et al.
Publicado: (2013)

ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor Olaparib
por: Wilson, Zena, et al.
Publicado: (2022)

BRD4 Inhibitor Inhibits Colorectal Cancer Growth and Metastasis
por: Hu, Yuan, et al.
Publicado: (2015)

Synergetic Effects of PARP Inhibitor AZD2281 and Cisplatin in Oral Squamous Cell Carcinoma in Vitro and in Vivo
por: Yasukawa, Masaaki, et al.
Publicado: (2016)

Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper
por: Illuzzi, Giuditta, et al.
Publicado: (2022)

Potent BRD4 inhibitor suppresses cancer cell-macrophage interaction
por: Yin, Mingzhu, et al.
Publicado: (2020)

LDH-A inhibitors as remedies to enhance the anticancer effects of PARP inhibitors in ovarian cancer cells
por: Xiang, Jiangdong, et al.
Publicado: (2021)

The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma
por: Derenzini, E, et al.
Publicado: (2011)

The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma
por: Derenzini, E, et al.
Publicado: (2014)

MUS81 Inhibition Enhances the Anticancer Efficacy of Talazoparib by Impairing ATR/CHK1 Signaling Pathway in Gastric Cancer
por: Wang, Tao, et al.
Publicado: (2022)

PARP inhibitors
por: Anwar, Maheen, et al.
Publicado: (2015)

Tert-butylhydroquinone mitigates Carbon Tetrachloride induced Hepatic Injury in mice
por: Li, Ruidong, et al.
Publicado: (2020)

Protective Role of 4-Octyl Itaconate in Murine LPS/D-GalN-Induced Acute Liver Failure via Inhibiting Inflammation, Oxidative Stress, and Apoptosis
por: Li, Ruidong, et al.
Publicado: (2021)

4-OI Attenuates Carbon Tetrachloride-Induced Hepatic Injury via Regulating Oxidative Stress and the Inflammatory Response
por: Li, Ruidong, et al.
Publicado: (2021)

BRD4 inhibitor and histone deacetylase inhibitor synergistically inhibit the proliferation of gallbladder cancer in vitro and in vivo
por: Liu, Shilei, et al.
Publicado: (2019)

Nrf2 inhibition increases sensitivity to chemotherapy of colorectal cancer by promoting ferroptosis and pyroptosis
por: Huang, Yongzhou, et al.
Publicado: (2023)

Hepatoprotective Role of 4-Octyl Itaconate in Concanavalin A-Induced Autoimmune Hepatitis
por: Yang, Wenchang, et al.
Publicado: (2022)

The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells
por: Arun, Banu, et al.
Publicado: (2015)

PARP inhibitors: the race is on
por: Brown, Jessica S, et al.
Publicado: (2016)

Combined treatment of disulfiram with PARP inhibitors suppresses ovarian cancer
por: Tang, Bin, et al.
Publicado: (2023)

BRD4 inhibitors block telomere elongation
por: Wang, Steven, et al.
Publicado: (2017)

The mTOR inhibitor AZD8055 inhibits proliferation and glycolysis in cervical cancer cells
por: LI, SHAORU, et al.
Publicado: (2013)

An iridium(iii)-based irreversible protein–protein interaction inhibitor of BRD4 as a potent anticancer agent
por: Zhong, Hai-Jing, et al.
Publicado: (2015)

The BRD4 Inhibitor dBET57 Exerts Anticancer Effects by Targeting Superenhancer-Related Genes in Neuroblastoma
por: Jia, Si-Qi, et al.
Publicado: (2022)

Blocking PARP activity with the inhibitor veliparib enhances radiotherapy sensitivity in endometrial carcinoma
por: Wang, Jing, et al.
Publicado: (2022)

The novel combination of dual mTOR inhibitor AZD2014 and pan-PIM inhibitor AZD1208 inhibits growth in acute myeloid leukemia via HSF pathway suppression
por: Harada, Masako, et al.
Publicado: (2015)

The PARP1 Inhibitor AZD5305 Impairs Ovarian Adenocarcinoma Progression and Visceral Metastases in Patient-derived Xenografts Alone and in Combination with Carboplatin
por: Dellavedova, Giulia, et al.
Publicado: (2023)

Metabolite itaconate in host immunoregulation and defense
por: Yang, Wenchang, et al.
Publicado: (2023)

Effects of a checkpoint kinase inhibitor, AZD7762, on tumor suppression and bone remodeling
por: Wang, Luqi, et al.
Publicado: (2018)

Preparation data of the bromodomains BRD3(1), BRD3(2), BRD4(1), and BRPF1B and crystallization of BRD4(1)-inhibitor complexes
por: Hügle, Martin, et al.
Publicado: (2016)

NADP(+) is an endogenous PARP inhibitor in DNA damage response and tumor suppression
por: Bian, Chunjing, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_cvsl920evbhaun18t2l747fkrh